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Protein turnover and quality control by the proteasome is of paramount importance for cell homeostasis.
Dysfunction of the proteasome is associated with aging processes and human diseases such as neuro-
degeneration, cardiomyopathy, and cancer. The regulation, i.e. activation and inhibition of this funda-
mentally important protein degradation system, is still widely unexplored. We demonstrate here that the
evolutionarily highly conserved type II triple-A ATPase VCP and the proteasome inhibitor PSMF1/PI31
interact directly, and antagonistically regulate proteasomal activity. Our data provide novel insights into
the regulation of proteasomal activity.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Homeostasis of cells is highly dependent on the integrity of the
proteasome, which hydrolyzes intracellular proteins into small
peptides, thus regulating protein turnover and removal of mis-
folded and poly-ubiquitinated proteins [1,2]. Proteasome dysfunc-
tion has been implicated in a wide variety of human diseasesMedical Faculty, University of
ermany.
y, University Hospital Erlan-
(C.S. Clemen), rolf.schroeder@
Inc. This is an open access article uincluding neurodegenerative disorders, muscular dystrophies,
cardiomyopathies, immune defects, metabolic diseases, and cancer
[3,4].
The 20S core of the proteasome is a 700 kDa barrel-shaped
structure composed of four stacked rings. The two outer rings are
formed by seven different a-subunits (PSMA1-7 in mammals) that
function as entry sites, whereas the two inner rings, which consist
of seven different b-subunits (PSMB1-7), exert the trypsin-,
chymotrypsin-, and caspase-like proteolytic activities. Regulation
of the proteasome is a complex and partially unresolved issue.
Activation of the 20S core under physiological conditions requires
binding of the 19S regulatory particle (synonym PA700) to one of
the outer rings leading to the formation of the functionally active
26S proteasome. Alternatively, the 20S core can be activated bynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mers (11S complexes), and the PA200 (PSME4) monomer [1,2,5,6].
Physiological inhibition of the proteasome is achieved by PSMF1
(proteasome inhibitor PI31 subunit [7]) binding. PSMF1 is a highly
conserved, proline-rich 31 kDa protein that inhibits the proteaso-
mal activities by either direct binding to the outer rings of the 20S
proteasome or by competing with the activating particles for 20S
binding [8e10].
VCP (valosin containing protein; orthologs known as VAT,
CDC48, CdcD, TER94, p97) is a ubiquitously expressed and evolu-
tionarily highly conserved type II triple-A ATPase involved in awide
variety of essential cellular processes comprising nuclear envelope
reconstruction, the cell cycle, post-mitotic Golgi reassembly, sup-
pression of apoptosis, DNA damage response, and protein quality
control mechanisms [11]. The essential role of VCP in human cells is
highlighted by the observation that point mutations of the VCP
gene cause three autosomal dominant disorders, namely IBMPFD
(inclusion body myopathy with early onset Paget's disease of bone
and frontotemporal dementia) [12], ALS14 (amyotrophic lateral
sclerosis with or without frontotemporal dementia) [13], and a
form of HSP (hereditary spastic paraplegia) [14].
Here, we demonstrate that VCP and PSMF1 interact directly, and
regulate the activity of the fundamentally important proteasome in
an antagonistic fashion.2. Materials and methods
2.1. Lumier technique
The luminescence-based mammalian interactome mapping
(Lumier) technique allows detection and quantitation of pro-
teineprotein interactions in mammalian cells [15]. The method is
based on a double-transfection with plasmids coding for the pro-
teins of interest with either a Renilla luciferase or a Protein A tag.
The original protocol of the Lumier technique was modiﬁed, opti-
mized, and used as described in the Supplementary Materials and
Methods section.2.2. Proteasomal activity assays
In this study, the chymotrypsin-like proteasomal activity was
monitored based on the cleavage of succinyl-LLVY-aminoluciferin.
In a secondary reaction, the released aminoluciferin is processed
by the Fireﬂy luciferase and used for luminometry. This
luminescence-based technique has the experimental advantage
that it allows a direct determination of the proteasomal activity
during the entire course of the experiment. In contrast, the
commonly used ﬂuorescence-based assay detects the increment of
the 7-amino-4-methylcoumarin cleavage product thus limiting the
measurement to the initial state. For details on our optimized
protocol please refer to the Supplementary Materials and Methods
Section.2.3. Molecular modeling
N-PSMF1 (PDB entry 2VT8), VCP-ND1 (PDB entry 3QQ8), FAFA1-
UBX in complex with the VCP-ND1 domain (PDB entry 3QQ8), and
20S proteasome (PDB entry 1YAU) were used for rigid body dock-
ing. Initial complexes of N-PSMF1:VCP-ND1 and [N-PSMF1]7:20S
were then subjected to molecular dynamics simulations
(t¼ 22.5 ns and t¼ 10 ns, respectively). Detailed information on the
molecular modeling procedures is provided in the Supplementary
Materials and Methods Section.2.4. Miscellaneous methods
Further standard methods and an antibody list are given in the
Supplementary Materials and Methods Section. Generation of mice
haploinsufﬁcient for VCP is described in the legend to Fig. S1.
3. Results
3.1. VCP directly interacts with the proteasome inhibitor PSMF1
To identify novel and disease relevant VCP binding partners, we
have previously performed VCP co-immunoprecipitation experi-
ments, which resulted in the identiﬁcation of PSMF1 as a putative
candidate (Supplementary Tables 1 and 2 in Ref. [16]). By means of
luminescence-based mammalian interactome mapping (Lumier)
[15], we investigated potential interactions of VCP with various
target proteins. Using this novel experimental approach, we ﬁrst
conﬁrmed VCP multimer formation (Fig. 1A) as well as its in-
teractions with the previously established VCP binding partners
Ufd1 and Npl4. More importantly, we could demonstrate an
interaction of VCP and PSMF1 within a similar dynamic range as
observed for VCP and Ufd1 or Npl4 (Fig. 1B). Using pull-down as-
says with puriﬁed recombinant proteins, we could validate that
VCP and its novel binding partner PSMF1 interact directly (Fig. 1C).
3.2. Reduced VCP levels cause decreased proteasomal activity
Previous studies showed that the targeted ablation of VCP in
mouse, fruit ﬂy, yeast, and the protist Trypanosoma brucei was le-
thal in all these organisms [17e20]. In VCP haploinsufﬁcient mice
(Fig. S1), which displayed a ~30% and ~40% reduction of the VCP
mRNA and protein levels, respectively (Fig. 2AeC), we noted an
increase of poly-ubiquitinated proteins (Fig. 2C). Using a highly
sensitive luminescence-based proteasomal activity assay, we
studied the chymotrypsin-like activity in lower hind limb muscles
derived from three months old mice. Here, the VCP hap-
loinsufﬁcient mice showed a signiﬁcant reduction (~32%) of the
speciﬁc proteasomal activity as compared to wild-type littermates
(Fig. 2D), while the expression levels of 19S and 20S proteasome
complexes as well as PSMF1 remained unchanged (Fig. 2C).
3.3. VCP and PSMF1 antagonistically regulate proteasome activity
To investigate potential roles of VCP and PSMF1 on proteasomal
activity in vitro, we ﬁrst added puriﬁed recombinant human VCP
(100% sequence identity to murine VCP) to skeletal muscle lysates
derived from the VCP haploinsufﬁcient mice. This resulted in a
dose-dependent increase of proteasomal activity (Fig. 3A). This
effect, however, was not observed in analogous experiments using
either puriﬁed human 26S or 20S proteasomes instead of the tissue
lysate (Fig. 3B). The latter ﬁnding argues against a direct stimula-
tory effect of VCP on the proteasome and favors the presence of a
co-factor in the tissue lysate.
We considered PSMF1 as a promising candidate and therefore
used both puriﬁed recombinant VCP and PSMF1 proteins to analyze
their activating and inhibiting effects on 20S proteasomal activity
in vitro (Fig. 3C). Upon addition of VCP, the activity of puriﬁed
proteasome remained unchanged (Fig. 3C, part i, red line), whereas
the addition of PSMF1 inhibited proteasomal activity as expected
(part i, blue line). The subsequent addition of PSMF1 to the reaction
already containing VCP signiﬁcantly reduced proteasomal activity
(part ii, red line). The addition of VCP to the reactions containing
PSMF1 antagonized the inhibitory effects (part iii, red and blue
lines) and resulted in a signiﬁcant increase in proteasomal activity.
The subsequent addition of more PSMF1 resulted again in
Fig. 1. VCP interacts directly with PSMF1 (proteasome inhibitor PI31 subunit). A, B, VCP protein interaction analyses using the Lumier-technique, which is based on a double-
transfection with plasmids coding for Renilla luciferase- (Luc) and Protein A- (Prot A) tagged proteins. Negative controls (normalized luminescence signal intensity set to 1,
dotted lines, left columns in A and B) are based on the sole transfection of the luciferase-tagged proteins. Statistical signiﬁcance was calculated by Student's t-test; n indicates the
number of independent experiments; error bars indicate standard errors of the mean. A, the high normalized luminescence signal intensity of VCP reﬂects its hexamerization state.
To visualize the dynamic range of the Lumier method, the luminescence of a coronin protein (CRN2/Coro1C) that forms trimers is shown. B, lumier analysis shows binding of VCP to
PSMF1 with binding strength similar to those of the two well-established VCP binding partners Ufd1 and Npl4. Further, the Lumier method showed a lack of interaction of VCP with
the 20S proteasome subunit PSMA1. C, conﬁrmation of the direct VCP e PSMF1 interaction by pull-down assays employing puriﬁed recombinant human VCP (untagged) and PSMF1
(GST-tagged) proteins. Negative controls were GST-PSMA1 and GST alone. Asterisks, degradation products of PSMF1 as determined by mass spectrometry. For illustration, the
original immunoblots were cropped to display the relevant sections.
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reversed by further addition of VCP (data not shown). To assess the
molar ratios of the reaction mixtures, proteins were precipitated at
the end of the experiments. Analysis by SDS-PAGE showed that the
observed effects of PSMF1 and VCP on the proteasomal activity are
stoichiometric (Fig. 3D; ratios are indicated).
We previously reported that a strain of the model organism
Dictyostelium discoideum deﬁcient for the core autophagy protein
ATG9 (ATG9KO strain) has an intrinsic and severe defect of protea-
somal activity [21]. To assess whether VCP can also inﬂuence the
proteasomal activity in vivo, we utilized this strain and over-
expressed RFP-tagged VCP in the ATG9KO cells. Here, we found
that an approximately 2-fold increase of VCP protein levels (data
not shown) fully restored the proteasomal activity (Fig. 3E).3.4. PSMF1 may act as a multimer
It is currently unknown whether the PSMF1-induced inactiva-
tion of the proteasome is due to binding of monomeric or multi-
meric PSMF1 to the 20S core. Therefore, we performed in silico
analyses, which indicated that multimers of PSMF1 may bind in
place of 19S regulatory particles and thus lead to the formation of
catalytically inactive [PSMF1]n:20S proteasome complexes. The
simulated model shown here assumes n ¼ 7, i.e. a heptameric ring
of PSMF1 on top of the 20S proteasome (Fig. 4A); however, we
cannot exclude the possibility of a hexameric PSMF1 assembly on
the 20S particle. Experimental evidence for PSMF1 multimers
comes from clear-native PAGE analyses, which indicated the for-
mation of trimers, hexamers, and nonamers (Fig. 4B).
Fig. 2. VCP haploinsufﬁcient mice show reduced speciﬁc proteasomal activity and increased protein ubiquitination. A, quantitative real-time RT-PCR analyses of VCP mRNA
expression in skeletal muscle tissue derived from wild-type (WT) and heterozygous (HET) congenic B6J.129S2-Vcptm1(ko)Cscl&Rfsr mice. Mean values and standard errors were
obtained by four-fold repeated measurements in two animals per genotype. B, densitometric analyses of VCP immunoblots. Mean values and standard errors were calculated by
analyzing 25 and 29 bands derived fromwild-type and heterozygous mice, respectively. Columns in A and B represent relative values with wild-type expression scaled to 1. p-values
were calculated by Student's t-test. The reduced levels of VCP mRNA and protein demonstrate a VCP haploinsufﬁciency. C, the reduced VCP protein expression level is associated
with increased protein ubiquitination (ubiq; note that this is a pattern of increased ubiquitination levels typical for skeletal muscle), whereas the levels of PSMF1, 19S, and 20S
proteasome were unchanged. GAPDH was used as loading control. For illustration, the original immunoblots were cropped to display the relevant sections. D, luminescence-based
proteasomal activity measurements in skeletal muscle tissue from lower hind limbs of three months old mice. The speciﬁc proteasomal activity is normalized to the amount of
proteasome. Note that the chymotrypsin-like proteasomal activity in VCP haploinsufﬁcient mice is signiﬁcantly reduced. Mean values and standard errors were obtained from six
independent experiments; p-values were calculated by Student's t-test; activity of wild-type mice was set to 1.
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Fig. 3. VCP and PSMF1: antagonistic regulators of proteasomal activity. A, addition of recombinant human VCP to lysates prepared from skeletal muscle tissue derived from VCP
haploinsufﬁcient mice increased proteasomal activity in a dose dependent manner. Mean values and standard errors were obtained from two independent experiments. Columns
represent relative values of the normalized chymotrypsin-like activity; proteasomal activity without addition of VCP was set to 1. B, in a corresponding assay using a purchased
preparation of human 26S proteasome derived from HEK293 cells, VCP did not increase proteasomal activity. C, luminescence-based proteasomal activity of human 20S proteasome
derived from red blood cells alone, or in the presence of either proteasomal inhibitor AdaAhx3L3VS, or recombinant human VCP puriﬁed from bacteria, or recombinant human
PSMF1 puriﬁed from HEK293 cells. Reactions were monitored until steady-state was reached (panel (i); y-axis: counts per second). The reactions were continued after the addition
of PSMF1 or VCP as indicated by the arrowheads (panels (ii)e(iv); y-axis: normalized activity; activity of 20S alone was used as reference and set to 1). Gaps before the arrowheads
indicate a delay of three minutes before measurements were resumed after each protein addition. The data shownwere derived from a single continuous experiment that had been
independently conducted three times with the same experimental design; three more experiments with identical results employed 20S proteasome prepared from 293TN cells in
conjunction with recombinant human GST-PSMF1 puriﬁed from E. coli. D, visualization of the stoichiometry of PMSF1 and VCP used in C. Proteins of the reaction mixtures in C (see
the color codes) were chloroform-methanol precipitated after completion of the reactions, separated by SDS-PAGE, and stained by Coomassie brilliant blue (the horizontal line
within the image indicates different contrast adjustments made to the upper and lower parts). Since only 100 ng of proteasome were used per reaction, subunits of the proteasome
are not visible; the single band at approximately 70 kDa corresponds to BSA present in the proteasome buffer. Contaminations of puriﬁed PSMF1 with bovine actin and tubulin as
well as horse Hsp90 are indicated by open circles. Reactions annotated with an asterisk did not receive PSMF1, but contained a BSA fragment of similar size as determined by mass
spectrometry. The prominent band at 64 kDa corresponds to the recombinant Fireﬂy luciferase (LucLa). Molar ratios of PSMF1 to 20S proteasome and of PSMF1 to VCP at the start of
the experiment are indicated. VCP immunoblotting conﬁrmed that the proteasome preparations were free of VCP that may have been co-puriﬁed (the two lines shown were
digitally rearranged to omit dispensable lines). E, in vivo rescue of the speciﬁc proteasomal activity by over-expression of RFP-tagged VCP in a previously reported D. discoideum
ATG9KO strain, which exhibits a drastically reduced proteasomal activity [21]. Activity of AX2 wild-type cells was set to 1. We previously reported a similar ﬁnding [21], however, for
the purpose of the present study we had performed three additional measurements to further substantiate the initial ﬁnding.
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Fig. 4. PSMF1 interactions with 20S proteasome and VCP: a model for the antagonistic regulation of proteasomal activity. A, in silico model of a PSMF1 multimer replacing the 19S
regulatoryparticle leading to the formation of a catalytically inactive [N-PSMF1]n:20Sproteasome (for illustration, n¼7). TheN-terminal ends ofN-PSMF1project radially to the outside
and the C-terminal ends into the inner cavity of the heptameric ring. The putative binding site of anN-PSMF1monomer (cartoon representation of secondary structure elements) to the
PSMA1-7 ring is indicated in green, the binding site toVCP inmagenta; the latter contains the amino acid sequence LYVwhichmatches anHbYXmotif that iswell-known formodulators
of proteasomal activity. The aminoacid stretchgiven inyellowrepresents putative interaction interfaceswith both theproteasomeandVCP. B, recombinantpuriﬁedGST-PSMF1andGST
were separated by clear-native PAGE. Whereas GST remains monomeric, PSMF1 forms timers, hexamers, and nonamers. Asterisk, contamination by bacterial GroEL, as determined by
mass spectrometry. C, in silicomodel of the PSMF1-VCP interaction. N-PSMF1:VCP-ND1 illustrates the potential binding mode of N-PSMF1 (cartoon representation in turquois) with
VCP-ND1 (surface representationwithmapped electrostatics in red (negative potential) and blue (positive potential)). The equilibratedmodel of N-PSMF1:VCP-ND1 and the hexameric
VCP structure were used to construct the [N-PSMF1:VCP]6 complex (surface representationwith PSMF1 in bluish colors and the VCP monomers in orange and green). D, model of the
PSMF1 and VCP mediated antagonistic regulation of proteasomal activity. Surface representations of the 26S proteasome (electron microscopy reconstruction, PDB entry 4C0V), N-
PSMF1 and VCP. See Discussion section for details.
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C.S. Clemen et al. / Biochemical and Biophysical Research Communications 463 (2015) 1210e12171216The binding sites between PSMF1 and VCP have not yet been
experimentally established. Based on the structural similarities
between PSMF1 and FAFA1-UBX, another VCP binding partner, we
performed molecular modeling addressing the PSMF1-VCP inter-
action. As a result of our in silico modeling, the complex of N-
PSMF1:VCP-ND1 (Fig. 4C) illustrates the putative binding mode of
N-PSMF1 (cartoon representation in turquois) with VCP-ND1
(surface representation with mapped electrostatics in red (nega-
tive potential) and blue (positive potential)). VCP assembles into
hexamers with its ATPase domains forming a central cylinder that
is surrounded by the N-terminal CDC48 domains [22]. We therefore
used the N-PSMF1:VCP-ND1 model and the hexameric VCP struc-
ture to ﬁnally construct a [N-PSMF1:VCP]6 complex (surface rep-
resentation with PSMF1 in bluish colors and the VCP monomers in
orange and green) (Fig. 4C).4. Discussion
Beyond a multitude of other functions, VCP has also been
attributed an important role in the degradation of poly-
ubiquitinated proteins via the proteasome. A knock-down of VCP
in HeLa cells led to the accumulation of poly-ubiquitinated proteins
[23]. Previous studies demonstrated that several substrates of the
ubiquitin-proteasomal system need VCP and its co-factors in order
to be properly processed [24,25]. Moreover, VCP was detected in
proteasomal puriﬁcations [26e29], and a more recent study
demonstrated that VCP associated with the 19S sub-complex of the
proteasome upon proteasomal inhibition or over-expression of VCP.
This study also indicated that the VCP co-factors Ufd1 and Npl4
promote an enrichment of VCP at the inhibited proteasome [30].
PSMF1 on the other hand was generally described as a potent
inhibitor of proteasomal activity [7e10]. In contrast, a recent study
suggested that the situation may be more complex as ADP-
ribosylated PSMF1 may stimulate proteasomal activity [8]. This
latter mechanism relies on abolished binding of the post-
translationally modiﬁed PSMF1 to the 20S proteasome core,
which instead binds and sequesters 19S assembly chaperones, thus
liberating 19S regulatory particles for the formation of catalytically
active 26S proteasomes. However, this suggestion has been chal-
lenged by the ﬁndings that the ribosylation inhibitor XAV939 did
not decrease proteasomal activity, and that ADP-ribosylation of
PSMF1 could not be detected by immunoblotting [31].
Based on our experimental work in conjunction with in silico
modeling, we delineate an extended mechanism of proteasome
regulation, in which PSMF1 and VCP antagonistically regulate
proteasomal activity (Fig. 4D). The catalytically active 26S protea-
some (top) continually assembles and disassembles in vivo into the
20S core particle and the 19S regulatory complex (transition 1).
Only the “free” 20S proteasome (left) seems to interact with PSMF1
(transition 2), as a recent study showed that PSMF1 was able to
suppress the assembly of 26S proteasome from 19S and 20S par-
ticles, but had no effect on preformed 26S proteasome in vitro [31].
The catalytically inactive state of the proteasome is the
[PSMF1]n:20S complex (bottom; PSMF1 in bluish colors, for illus-
tration, n ¼ 7). As previously proposed [10], PSMF1 molecules may
indeed act as caps of the 20S proteasomes with the C-terminal
regions of the PSMF1 monomers blocking the entry of substrates to
the proteolytically active sites inside the 20S core particle. This
PSMF1-mediated inactivation of the proteasome can be counter-
acted by increasing levels of VCP. In our mechanistic model, VCP
sequesters PSMF1 from the [PSMF1]n:20S complex and gives rise to
[PSMF1:VCP]6 complexes (transition 3). This ﬁnally enables the re-
assembly of catalytically active 26S proteasomes from “free” 20S
core and 19S regulatory particles (transition 4).We thus propose that in addition to its postulated roles of
extracting misfolded proteins from the ER and shuttling poly-
ubiquitinated proteins to the proteasome [32,33], VCP activates
the proteasome by counteracting the inhibitory effect of PSMF1.
Importantly, our model does not exclude activation of the protea-
some by ADP-ribosylation of PSMF1 [8]. Both regulatory mecha-
nisms would lead to re-assembly and activation of the 26S
proteasome and facilitate the turnover of degradation-prone pro-
teins. Our data thus provide novel, fundamental insights into the
basic regulation of proteasomal activity.
Acknowledgments
We thank Carolin Berwanger and Maria Stumpf for excellent
technical assistance. Ufd1 and Npl4 expression plasmids were
kindly provided by Annett B€oddrich (Max Delbrück Center for
Molecular Medicine, Berlin, Germany) and Hemmo Meyer (Uni-
versity of Duisburg-Essen, Germany), respectively. pDEST-RLuc
(originally named pcDNA3-Rluc-GW) and pDEST-ProtA (originally
named pTREX-Dest30-ProtA) vectors for the Lumier experiments
were generously provided by Manfred K€ogl (Preclinical Target
Development, and Genomics and Proteomics Core Facilities, DKFZ,
Heidelberg, Germany).
Grant support by the German Research Foundation (DFG)within
the framework of the multi-location research group FOR1228
(grants CL 381/3-2 to CSC, HA 2092/23-2 to FGH, RO 2173/4-2 to
WR, JU 2859/1-2 to SJ, EI 399/7-2 to LE, and SCHR 562/9-2 to RS),
within the collaborative research consortium 815 (project Z1 to
IW), and for individual research projects (grants CL 381/1-1 to CSC
and SCHR 562/7-1 to RS), by the Fritz-Thyssen-Foundation (grant
10.07.1.165 to RS and CSC), the Australian Research Council (ARC)
(grant LE120100071 to AH), by K€oln Fortune (to CSC and LE), and by
the Interdisciplinary Center for Clinical Research (IZKF) of the
Clinical Center Erlangen (to MT) is gratefully acknowledged.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.bbrc.2015.06.086.
Transparency document
Transparency document related to this article can be found
online at http://dx.doi.org/10.1016/j.bbrc.2015.06.086.
References
[1] A.V. Sorokin, E.R. Kim, L.P. Ovchinnikov, Proteasome system of protein
degradation and processing, Biochemistry (Mosc) 74 (2009) 1411e1442.
[2] T. Jung, B. Catalgol, T. Grune, The proteasomal system, Mol. Asp. Med. 30
(2009) 191e296.
[3] A.V. Gomes, Genetics of proteasome diseases, Scientiﬁca 2013 (2013)
629e637.
[4] E. Jankowska, J. Stoj, P. Karpowicz, et al., The proteasome in health and dis-
ease, Curr. Pharm. Des. 19 (2013) 1010e1028.
[5] M. Rechsteiner, C.P. Hill, Mobilizing the proteolytic machine: cell biological
roles of proteasome activators and inhibitors, Trends Cell Biol. 15 (2005)
27e33.
[6] B. Dahlmann, Proteasomes, Essays Biochem. 41 (2005) 31e48.
[7] M. Chu-Ping, C.A. Slaughter, G.N. DeMartino, Puriﬁcation and characterization
of a protein inhibitor of the 20S proteasome (macropain), Biochim. Biophys.
Acta 1119 (1992) 303e311.
[8] P.F. Cho-Park, H. Steller, Proteasome regulation by ADP-ribosylation, Cell 153
(2013) 614e627.
[9] D.M. Zaiss, S. Standera, H. Holzhutter, et al., The proteasome inhibitor PI31
competes with PA28 for binding to 20S proteasomes, FEBS Lett. 457 (1999)
333e338.
[10] S.L. McCutchen-Maloney, K. Matsuda, N. Shimbara, et al., cDNA cloning,
expression, and functional characterization of PI31, a proline-rich inhibitor of
the proteasome, J. Biol. Chem. 275 (2000) 18557e18565.
C.S. Clemen et al. / Biochemical and Biophysical Research Communications 463 (2015) 1210e1217 1217[11] G.H. Baek, H. Cheng, V. Choe, et al., Cdc48: a Swiss army knife of cell biology,
J. Amino Acids 2013 (2013), 183421.
[12] G.D. Watts, J. Wymer, M.J. Kovach, et al., Inclusion body myopathy associated
with Paget disease of bone and frontotemporal dementia is caused by mutant
valosin-containing protein, Nat. Genet. 36 (2004) 377e381.
[13] J.O. Johnson, J. Mandrioli, M. Benatar, et al., Exome sequencing reveals VCP
mutations as a cause of familial ALS, Neuron 68 (2010) 857e864.
[14] S.T. de Bot, H.J. Schelhaas, E.J. Kamsteeg, et al., Hereditary spastic paraplegia
caused by a mutation in the VCP gene, Brain 135 (2012) e223.
[15] M. Barrios-Rodiles, K.R. Brown, B. Ozdamar, et al., High-throughput mapping
of a dynamic signaling network in mammalian cells, Science 307 (2005)
1621e1625.
[16] C.S. Clemen, K. Tangavelou, K.H. Strucksberg, et al., Strumpellin is a novel
valosin-containing protein binding partner linking hereditary spastic para-
plegia to protein aggregation diseases, Brain 133 (2010) 2920e2941.
[17] J.M. Müller, K. Deinhardt, I. Rosewell, et al., Targeted deletion of p97 (VCP/
CDC48) in mouse results in early embryonic lethality, Biochem. Biophys. Res.
Commun. 354 (2007) 459e465.
[18] K.U. Fr€ohlich, H.W. Fries, M. Rudiger, et al., Yeast cell cycle protein CDC48p
shows full-length homology to the mammalian protein VCP and is a member
of a protein family involved in secretion, peroxisome formation, and gene
expression, J. Cell Biol. 114 (1991) 443e453.
[19] J.R. Lamb, V. Fu, E. Wirtz, et al., Functional analysis of the trypanosomal AAA
protein TbVCP with trans-dominant ATP hydrolysis mutants, J. Biol. Chem.
276 (2001) 21512e21520.
[20] A. Leon, D. McKearin, Identiﬁcation of TER94, an AAA ATPase protein, as a
bam-dependent component of the Drosophila fusome, Mol. Biol. Cell 10
(1999) 3825e3834.
[21] K. Arhzaouy, K.H. Strucksberg, S.M. Tung, et al., Heteromeric p97/p97(R155C)
complexes induce dominant negative changes in wild-type and autophagy 9-
deﬁcient dictyostelium strains, PloS One 7 (2012) e46879.
[22] B. DeLaBarre, A.T. Brunger, Complete structure of p97/valosin-containing
protein reveals communication between nucleotide domains, Nat. Struct.
Biol. 10 (2003) 856e863.[23] C. Wojcik, M. Yano, G.N. DeMartino, RNA interference of valosin-containing
protein (VCP/p97) reveals multiple cellular roles linked to ubiquitin/
proteasome-dependent proteolysis, J. Cell Sci. 117 (2004) 281e292.
[24] F. F€orster, J.M. Schuller, P. Unverdorben, et al., Emerging mechanistic insights
into AAA complexes regulating proteasomal degradation, Biomolecules 4
(2014) 774e794.
[25] T. Zhang, Y. Ye, The ﬁnal moments of misfolded proteins en route to the
proteasome, DNA Cell Biol. 33 (2014) 477e483.
[26] H.C. Besche, W. Haas, S.P. Gygi, et al., Isolation of mammalian 26S protea-
somes and p97/VCP complexes using the ubiquitin-like domain from HHR23B
reveals novel proteasome-associated proteins, Biochemistry 48 (2009)
2538e2549.
[27] C. Guerrero, T. Milenkovic, N. Przulj, et al., Characterization of the proteasome
interaction network using a QTAX-based tag-team strategy and protein
interaction network analysis, Proc. Natl. Acad. Sci. U. S. A. 105 (2008)
13333e13338.
[28] T. Shibatani, E.J. Carlson, F. Larabee, et al., Global organization and function of
mammalian cytosolic proteasome pools: implications for PA28 and 19S reg-
ulatory complexes, Mol. Biol. Cell 17 (2006) 4962e4971.
[29] R.M. Dai, E. Chen, D.L. Longo, et al., Involvement of valosin-containing protein,
an ATPase co-puriﬁed with IkappaBalpha and 26 S proteasome, in ubiquitin-
proteasome-mediated degradation of IkappaBalpha, J. Biol. Chem. 273 (1998)
3562e3573.
[30] E. Isakov, A. Stanhill, Stalled proteasomes are directly relieved by P97
recruitment, J. Biol. Chem. 286 (2011) 30274e30283.
[31] X. Li, D. Thompson, B. Kumar, et al., Molecular and cellular roles of PI31
(PSMF1) protein in regulation of proteasome function, J. Biol. Chem. 289
(2014) 17392e17405.
[32] S. Braun, K. Matuschewski, M. Rape, et al., Role of the ubiquitin-selective
CDC48(UFD1/NPL4 )chaperone (segregase) in ERAD of OLE1 and other sub-
strates, EMBO J. 21 (2002) 615e621.
[33] S. Raasi, D.H. Wolf, Ubiquitin receptors and ERAD: a network of pathways to
the proteasome, Semin. Cell Dev. Biol. 18 (2007) 780e791.
